- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06389357
Retun-to-school Adaptation Program for Children With Cancer (web-based)
Efficacy of the Web-based Return-to-school Adaptation Program for Children Diagnosed With Cancer
The aim of this action research is to:
Stage 1: Conduct an in-depth investigation into the adaptation challenges faced by children aged 8-17 who are being treated for cancer during their return to school, from both the children's and parents' perspectives;
Stage 2: Develop a structured, evidence-based, and digitally accessible intervention program that addresses these identified needs;
Stage 3: Evaluate the feasibility and effectiveness of the intervention; and
Ultimately, based on all data gathered throughout the implementation process, continuously refine the intervention and analyze participant feedback holistically in order to establish a sustainable support model.
Study Overview
Status
Intervention / Treatment
Detailed Description
Importance of research There are disease-specific medical and psychosocial difficulties that children with a diagnosis of cancer may experience. Standard school nursing practices can be helpful in meeting the physical, emotional, psychological, social and academic needs of children. However, a standard of care that is decided to be applied on return to school has not been developed. Therefore, it is thought that standard school nursing practices are not sufficient to meet the health and educational needs of children with cancer diagnosis. In the world, plans have been made using practices/methods/models appropriate for the population in the school return process of children followed up with a diagnosis of cancer. It is recommended to develop back-to-school programmes as they can benefit the child, family, peers, teachers and school staff who are followed up with a diagnosis of cancer. In our study, we aim to manage the transition care schematically with the back-to-school protocol to be made between the school-family-hospital, and to ensure care coordination and the safety of the child. The fact that the intervention in the back-to-school adaptation programme will be made to the child, parents, teachers and peers shows a holistic approach to the needs.
Place of application:
It will be performed in the paediatric leukaemia outpatient clinic of the Children's Hospital.
Study Population The population of the study consisted of children who were followed up in the paediatric leukaemia outpatient clinic of the Children's Hospital with a diagnosis of cancer.
Sample of the study In Phase 1, it was observed that after a certain number of interviews, no new themes or concepts emerged, and the data began to repeat previously obtained information. Accordingly, it was concluded that data saturation had been reached, and the data collection process was terminated. The sample for Phase 1 consisted of 12 children and their parents (n = 12).
In Phase 3, the study was conducted using a pre-experimental research design with a single group consisting only of the intervention group during the school re-entry adaptation program.
In program evaluation studies, a medium effect size is generally considered sufficient for quantitative evaluation methods. Accordingly, an effect size (Cohen's f) of at least 0.25 is recommended (Crisan & Elliott, 2018). For sample size planning, our study determined the estimated sample size to be 24 participants, based on 80% power and a 5% margin of error. The program in phase-3 was completed with 20 children and their parents who agreed to participate in the program.
Data Collection Tools
Phase 1: Identifying the experiences of children diagnosed with cancer and their parents during the return-to-school process - Descriptive phenomenological study:
The Child and Parent Descriptive Information Form Semi-Structured Interview Form
Phase 3: Implementation and evaluation of the school re-entry adaptation program:
- Child and Parent Descriptive Information Form
- Data Collection Form for Children's Return to School Process
- Social Anxiety Scale for Children-Revised Version
- Social Anxiety Scale for Adolescents
- Paediatric Cancer Coping Scale
- Readiness to Return to School Scale for Children with Oncological Problems: 7-18 Age
- Process Evaluation Forms
Statistical analysis
Phase 1 - Qualitative Study:
The audio recordings of the interviews were transcribed. The qualitative data were analyzed using thematic content analysis via MAXQDA 2024 software. The steps of thematic analysis-transcription of the data, creation of codes, identification of themes, and reporting-were systematically followed to develop the context, main themes, and sub-themes. Codes were identified and grouped, which informed the final sub-theme and theme structure.
Sociodemographic characteristics collected during the qualitative phase were analyzed using SPSS version 30.0.0.0 and reported using frequencies and percentages.
Phase 3 - Implementation and Evaluation of the Program:
To assess the adaptation program, the normality of children's scale scores was evaluated using Shapiro-Wilk tests and skewness-kurtosis values. For variables that did not show a normal distribution, median values were reported (see Table 3.14).
The statistical significance of changes in scale scores over time within the sample group was examined using the Friedman test. A significance level of p ≤ 0.05 was accepted for all statistical tests. In cases where a statistically significant difference was found, Bonferroni-adjusted Wilcoxon Signed-Rank Tests were conducted to determine between which measurements the differences occurred, with a significance threshold set at p ≤ 0.01.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Cankaya
-
Ankara, Cankaya, Turkey (Türkiye), 06490
- Gizem Cakir
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Implementation and Evaluation of the School Re-entry Adaptation Program
Inclusion Criteria
For Children:
Aged between 8 and 17 years Diagnosed with cancer (leukemia, lymphoma, or solid tumor) For children diagnosed with leukemia, currently receiving or having completed maintenance therapy For children diagnosed with other cancer types, treatment has been completed or they are continuing outpatient treatment Have completed the treatment process but have not yet returned to school Have returned to school after treatment but discontinued again due to difficulties managing the adaptation process Have internet access Able to use the internet, computer, and phone Able to speak Turkish Consent to participate in the study
For Parents:
Own a computer or smartphone Have internet access Able to use the internet, computer, and phone Able to speak Turkish Consent to participate in the study
Exclusion Criteria
For Children:
Requiring special physical and/or mental care Having learning disabilities Having a psychological or medical diagnosis (e.g., severe depression) Diagnosed with brain tumor Diagnosed with osteosarcoma Receiving immunosuppressive therapy Experiencing a major stressful event within the past year (e.g., loss, surgery unrelated to cancer treatment) Preparing to take secondary or higher education entrance exams during the study period
For Parents:
Requiring special physical and/or mental care Having learning disabilities Having a psychological or medical diagnosis (e.g., severe depression)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Implementation and evaluation of the school re-entry adaptation program
Counselling interviews and workshops will be held simultaneously with the children receiving the web-based training.
There are 4 modules in total.
The first module lasts 2 weeks.
The counselling interview will start in the 2nd week.
Implementation will be completed in 5 weeks.
|
It includes 4 modules that develop children's communication, coping and social life skills and psychosocial preparation for the return to school process.
The modules include theoretical explanations, stories, workshops and counselling sessions.
Separate educational modules have been developed for parents, teachers, and peers.
Other Names:
As part of the needs assessment in Phase 1, individual interviews with children with cancer and their parents lasting approximately 20-30 minutes were conducted.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
social anxiety
Time Frame: Before the intervention, before starting school, one month after starting school, three months after starting school
|
Social anxiety scale fo children-revised.
Scores that can be obtained from the scale are between 18-90 and as the scale score increases, the level of social anxiety increases.
|
Before the intervention, before starting school, one month after starting school, three months after starting school
|
|
coping
Time Frame: Before the intervention, before starting school, one month after starting school, three months after starting school
|
Paediatric Cancer Coping Scale.
Scores that can be obtained from the scale are between 0-99 and coping strategies increase as the scale score increases.
|
Before the intervention, before starting school, one month after starting school, three months after starting school
|
|
back to school readiness
Time Frame: Before the intervention, before starting school, one month after starting school, three months after starting school
|
Back to school readiness scale for children with oncological problems: 7-18 years of age.
The score that can be obtained from the scale is between 0 and 152 and a higher score indicates an increase in school readiness.
|
Before the intervention, before starting school, one month after starting school, three months after starting school
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
process evaluation
Time Frame: 1st month and 3rd month after starting school
|
Return to School Process Data Collection Form
|
1st month and 3rd month after starting school
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Gizem Cakir, PhD, Gazi University Nursing Faculty
Publications and helpful links
General Publications
- Crisan A, Elliott M. How to evaluate an evaluation study? Comparing and contrasting practices in vis with those of other disciplines. IEEE Xplore. 2018; doi: 10.1109/BELIV.2018.8634420.
- Rabin C, Simpson N, Morrow K, Pinto B. Behavioral and psychosocial program needs of young adult cancer survivors. Qual Health Res. 2011 Jun;21(6):796-806. doi: 10.1177/1049732310380060. Epub 2010 Aug 12.
- Ellis SJ, Wakefield CE, Antill G, Burns M, Patterson P. Supporting children facing a parent's cancer diagnosis: a systematic review of children's psychosocial needs and existing interventions. Eur J Cancer Care (Engl). 2017 Jan;26(1). doi: 10.1111/ecc.12432. Epub 2016 Jan 18.
- Thompson AL, Christiansen HL, Elam M, Hoag J, Irwin MK, Pao M, Voll M, Noll RB, Kelly KP. Academic Continuity and School Reentry Support as a Standard of Care in Pediatric Oncology. Pediatr Blood Cancer. 2015 Dec;62 Suppl 5(Suppl 5):S805-17. doi: 10.1002/pbc.25760.
- Canter KS, Roberts MC. A systematic and quantitative review of interventions to facilitate school reentry for children with chronic health conditions. J Pediatr Psychol. 2012 Nov-Dec;37(10):1065-75. doi: 10.1093/jpepsy/jss071. Epub 2012 Jun 19.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Hematologic Diseases
- Lymphatic Diseases
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Leukemia, Myeloid
- Leukemia, Lymphoid
- Leukemia
- Hemic and Lymphatic Diseases
- Neoplasms
- Leukemia, Myeloid, Acute
- Lymphoma
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Health Care Quality, Access, and Evaluation
- Investigative Techniques
- Epidemiologic Methods
- Data Collection
- Health Care Evaluation Mechanisms
- Quality of Health Care
- Public Health
- Environment and Public Health
- Health Services
- Health Care Facilities Workforce and Services
- Community Health Services
- Behavioral Disciplines and Activities
- Mental Health Services
- Interviews as Topic
- Counseling
Other Study ID Numbers
- 1305G2024
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
Novartis PharmaceuticalsBristol-Myers SquibbTerminatedNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaItaly, Singapore, Australia, China, Germany, South Korea, Japan
-
SymBio PharmaceuticalsCompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, DiffuseJapan, Korea, Republic of
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Mantle Cell Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Lymphoplasmacytic... and other conditionsUnited States, Canada
-
Robert LowskyNational Cancer Institute (NCI); Janssen, LP; The Leukemia and Lymphoma Society; Rising Tide FoundationCompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Epizyme, Inc.CompletedFollicular Lymphoma | Marginal Zone Lymphoma | Advanced Solid Tumors | Mantle-Cell Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal LymphomaUnited Kingdom
-
IGM Biosciences, Inc.ADC Therapeutics S.A.TerminatedFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
Juno Therapeutics, a Subsidiary of CelgeneCompletedFollicular Lymphoma | Non-Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal B-cell Lymphoma | Mantle-cell LymphomaUnited States
-
Lymphoma Study AssociationCompletedLymphoma, Large B-Cell, Diffuse | Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone LymphomaFrance
-
Emory UniversityNational Cancer Institute (NCI); AstraZenecaRecruitingMantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Lymphoproliferative Disorder | Indolent Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
Clinical Trials on training and counselling
-
Odense University HospitalRegion of Southern DenmarkCompletedChronic Obstructive Pulmonary Disease (COPD)Denmark
-
UKK InstituteFinland's Slot Machine Association (RAY); Ministry of Education; Scientific Advisory...Completed
-
Air Liquide Healthcare SpainHospital Sant Joan de DeuCompleted
-
Huashan HospitalUnknown
-
Queen's University, BelfastRecruiting
-
University of California, San FranciscoNational Cancer Institute (NCI)CompletedSmoking Cessation | Second Hand Tobacco SmokeUnited States
-
RWTH Aachen UniversityNot yet recruitingBlended-care Counselling | Digital and Mental Literacy Training | App STEPSGermany
-
Sormland County Council, SwedenUppsala County Council, Sweden; Västmanland County Council, SwedenRecruiting
-
Biruni UniversityIstanbul UniversityCompleted
-
University Medical Centre LjubljanaSlovenian Research AgencyUnknownKidney Diseases | Chronic Kidney Diseases | Physical Activity | End Stage Renal Disease | Kidney FailureSlovenia